![]() | |
Names | |
---|---|
IUPAC name
2-(2-((3,5-Dimethyl-1H-pyrrol-2-yl)methylene)-3-methoxy-2H-pyrrol-5-yl)-1H-indole
| |
Other names
GX15-070
| |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
PubChem
CID
|
|
UNII | |
| |
| |
Properties | |
C20H19N3O | |
Molar mass | 317.392 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Obatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon, which has since been acquired by Teva Pharmaceuticals. [1] Several Phase II clinical trials were completed that investigated use of obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis. [2] [3] [4]
Obatoclax is an inhibitor of the Bcl-2 family of proteins. [5] This inhibition induces apoptosis in cancer cells, preventing tumor growth. Solubility has been an issue in the development of the drug. [6]
Clinical trial results have been published for treatment of acute myeloid leukemia, [7] small cell lung cancer, [8] Hodgkin's lymphoma, [9] and myelodysplastic syndromes. [10]
Teva halted a phase III trial in patients with lung cancer before it had begun, citing "business decisions" as the reason. [11]
![]() | |
Names | |
---|---|
IUPAC name
2-(2-((3,5-Dimethyl-1H-pyrrol-2-yl)methylene)-3-methoxy-2H-pyrrol-5-yl)-1H-indole
| |
Other names
GX15-070
| |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
PubChem
CID
|
|
UNII | |
| |
| |
Properties | |
C20H19N3O | |
Molar mass | 317.392 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Obatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon, which has since been acquired by Teva Pharmaceuticals. [1] Several Phase II clinical trials were completed that investigated use of obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis. [2] [3] [4]
Obatoclax is an inhibitor of the Bcl-2 family of proteins. [5] This inhibition induces apoptosis in cancer cells, preventing tumor growth. Solubility has been an issue in the development of the drug. [6]
Clinical trial results have been published for treatment of acute myeloid leukemia, [7] small cell lung cancer, [8] Hodgkin's lymphoma, [9] and myelodysplastic syndromes. [10]
Teva halted a phase III trial in patients with lung cancer before it had begun, citing "business decisions" as the reason. [11]